BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
MAINZ, Germany, April 22, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for...
Cancer
CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy
Expanded indication for this one-time infusion may provide patients with a potential period away from their multiple myeloma treatment as...
Evexta Bio Reports Progress towards Clinical Development of Rupitasertib in Advanced Breast Cancer
Evexta Bio Reports Progress towards Clinical Development of Rupitasertib in Advanced Breast Cancer Feedback from FDA following Type B meeting...
Transactions in Connection with Share Buy-back Program Genmab
Company Announcement COPENHAGEN, Denmark; April 22, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation...
Orion Corporation: Managers’ transactions – Veli-Matti Mattila
ORION CORPORATION MANAGERS’ TRANSACTIONS 22 APRIL 2024 at 9.45 EEST Orion Corporation: Managers’ transactions – Veli-Matti Mattila Orion Corporation has...
SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients
SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients Phase...
Angle PLC Announces US and EU Patents for Innovative CellKeep(TM) Slide
Proprietary cell recovery device and method eliminates over 70% of CTC cell loss from standard microscopy techniques increasing assay sensitivity...
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
FLORHAM PARK, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (the “Company”), a regenerative medicine company developing placental-derived allogeneic...
Cosmos Health Receives Nasdaq Notice on Late Filing of Its Form 10-K
CHICAGO, IL / ACCESSWIRE / April 19, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,...
Two Clinical Trials Identify a Better Way to Target Appropriate Antibiotics for Patients Hospitalized With Pneumonia or Urinary Tract Infection
Algorithm driven alerts help identify best antibiotic for patients with common infections in two 59-hospital trials, with implications to reduce...
Sunshine Biopharma’s Nora Pharma Receives Health Canada Approval for Niopeg(R), a Biosimilar of Neulasta(R)
NEW YORK, NY / ACCESSWIRE / April 19, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM), a pharmaceutical company offering and researching...
Preliminary Results for the Year Ended 31 December 2023
19 April 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”) Preliminary Results for the...
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
Alvotech, in agreement with Teva Pharmaceuticals, has signed an agreement with a strategic partner to bring to the U.S. market...
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
Alvotech, in agreement with Teva Pharmaceuticals, has signed an agreement with a strategic partner to bring to the U.S. market...
FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented...
Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company’s In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care
Catherine Miller Collis was instrumental in bringing about Jaguar's recent in-license agreement for FDA-approved Gelclair®, a protective gel for management...
Cantargia Publishes Annual Report for 2023
LUND, SE / ACCESSWIRE / April 18, 2024 / Cantargia (STO:CANTA)Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today announced that the annual...
CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 18, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company...
Notice of Annual General Meeting in Cantargia AB (publ)
LUND, SWEDEN / ACCESSWIRE / April 18, 2024 / Cantargia (STO:CANTA) The shareholders of Cantargia AB (publ) are invited to...
Cantargia Publishes New Data on the CAN10 Antibody, Detailing its Interaction with IL1RAP and Functional Inhibition
LUND, SE / ACCESSWIRE / April 17, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today reported publication of...